<div class="description">
<p><b>Government Publishing Office</b></p><p>U.S. Congress<br>House of Representatives<br>Committee on Energy and Commerce<br></p><p>21ST CENTURY CURES: EXAMINING WAYS TO COMBAT ANTIBIOTIC RESISTANCE AND FOSTER NEW DRUG DEVELOPMENT</p><p>Date(s) Held: 2014-09-19</p><p> 113th Congress, 2nd Session</p><p>GPO Document Source: &lt;a href="<a rel="nofollow" class="external free" href="https://www.gpo.gov/fdsys/pkg/CHRG-113hhrg93933/content-detail.html">https://www.gpo.gov/fdsys/pkg/CHRG-113hhrg93933/content-detail.html</a>" rel="nofollow"&gt;CHRG-113hhrg93933&lt;/a&gt;<br>Superintendents of Documents ID: Y 4.R 31/3</p><p>Witnesses:</p><ul><li>Janet Woodcock, Director, Center for Drug Evaluation and Research, U.S. Food and Drug Administration</li><li>Kenneth J. Hillan, Chief Executive Officer, Achaogen, Inc</li><li>Barbara Murray, President, Infectious Disease Society of America</li><li>Adrian Thomas, Vice President, Global Market Access and Global Public Health, Janssen Global Services, LLC</li><li>Kevin Outterson, Professor of Law, Boston University School of Law</li><li>Allan Coukell, Senior Director, Drugs and Medical Devices, The Pew Charitable Trusts</li><li>Dr. John H. Powers, Assistant Clinical Professor of Medicine, George Washington University School of Medicine</li></ul><p>Related Items:</p><ul><li>&lt;a href="<a rel="nofollow" class="external free" href="https://www.govtrack.us/congress/bills/113/hr820">https://www.govtrack.us/congress/bills/113/hr820</a>" rel="nofollow"&gt;United States House Bill 820  (113th Congress)&lt;/a&gt;</li><li>&lt;a href="<a rel="nofollow" class="external free" href="https://www.govtrack.us/congress/bills/113/hr3742">https://www.govtrack.us/congress/bills/113/hr3742</a>" rel="nofollow"&gt;United States House Bill 3742  (113th Congress)&lt;/a&gt;</li><li>Congressional Serial No. 113-178</li></ul><br>Subjects: 113th;House</div>
<div class="fn value">
Committee on Energy and Commerce</div>
Internet Archive identifier